<DOC>
	<DOCNO>NCT03060603</DOCNO>
	<brief_summary>The purpose study assess proliferative effect erythropoetin human endometrium tissue measure endometrial thickness , uterine artery subendometrial blood flow postmenopausal woman .</brief_summary>
	<brief_title>Proliferative Effects Erythropoietin Human Endometrium</brief_title>
	<detailed_description>20 postmenopausal woman plan treat erythropoietin alpha renal condition include study . Sample size calculate proper power analysis accept difference 1 mm endometrial thickness significant change . After informed consent , endometrial thickness ( mm ) , uterine artery subendometrial blood flow doppler ultrasonography ( RI , S/D ) measure . Same measurement repeat 3rd day 30th day . Patients ' age , BMI , co-morbidities , administer erythropoietin dos note . No adverse effect expect regard ultrasonographic examination . Date patient attend appointment repetitive examination uninterpretable doppler variable due atrophic uterus note miss data exclude study . Proper statistical analysis do .</detailed_description>
	<mesh_term>Uterine Diseases</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Clinically condition need erythropoietin treatment anemia due renal failure need hemodialysis . Must postmenopausal period Patients type malignancy Existence intracavitary mass may affect endometrial thickness blood flow endometrial polyp , myoma , intracavitary fluid etc . Intrauterine device Being Hormon replacement therapy Hysterectomized patient</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Endometrium</keyword>
	<keyword>Doppler Ultrasonography</keyword>
</DOC>